Compare Regeneron Pharmaceuticals Inc (REGN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Trip.com Group Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Trip.com Group Ltd trades at $38.9 (market cap $23.75B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.2× Trip.com Group Ltd's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Trip.com Group Ltd for 79 Days on average.
| REGN | TCOM | |
|---|---|---|
Market Cap | $76.14B | $23.75B |
Volume | 500,239 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $78.96 |
52-Week Low | $557.73 | $37.96 |
Typical Hold Time | 107 Days | 79 Days |
Enterprise Value | $70.85B | $15.91B |
Dividend Yield | 0.51% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Trip.com (TCOM) trades at $37.96, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 earnings of $1.07 per share, beating expectations, with revenue reaching $62.41 billion in 2025 and net income margin of 36.9%. Recent regulatory challenges and market volatility have pressured the stock, though analyst consensus remains overwhelmingly positive with a $56.64 price target.
The stock presents a value opportunity with attractive valuation multiples (P/E 7.34, EV/EBITDA 3.43) but faces near-term headwinds from regulatory changes and competitive pressures. Strong cash flow generation and international expansion provide upside potential, though investors should monitor execution risks amid shifting market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
